Martingale Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20M | Buy |
44,750
+1,529
| +4% | +$713K | 0.5% | 67 |
|
|
2025
Q4 | $19.6M | Buy |
43,221
+6,699
| +18% | +$2.89M | 0.5% | 69 |
|
|
2025
Q3 | $14.3M | Sell |
36,522
-4,760
| -12% | -$1.99M | 0.36% | 99 |
|
|
2025
Q2 | $18.4M | Sell |
41,282
-565
| -1% | -$260K | 0.45% | 85 |
|
|
2025
Q1 | $20.3M | Sell |
41,847
-9,360
| -18% | -$4.36M | 0.52% | 73 |
|
|
2024
Q4 | $20.6M | Sell |
51,207
-2,120
| -4% | -$983K | 0.5% | 71 |
|
|
2024
Q3 | $24.8M | Sell |
53,327
-9,345
| -15% | -$4.49M | 0.57% | 62 |
|
|
2024
Q2 | $29.4M | Sell |
62,672
-7,316
| -10% | -$3.18M | 0.64% | 49 |
|
|
2024
Q1 | $29.3M | Sell |
69,988
-6,464
| -8% | -$2.73M | 0.58% | 61 |
|
|
2023
Q4 | $31.1M | Sell |
76,452
-4,845
| -6% | -$1.79M | 0.64% | 51 |
|
|
2023
Q3 | $28.3M | Sell |
81,297
-594
| -0.7% | -$208K | 0.59% | 59 |
|
|
2023
Q2 | $28.8M | Sell |
81,891
-1,991
| -2% | -$671K | 0.56% | 66 |
|
|
2023
Q1 | $26.4M | Buy |
83,882
+697
| +0.8% | +$209K | 0.51% | 79 |
|
|
2022
Q4 | $24M | Sell |
83,185
-2,453
| -3% | -$748K | 0.47% | 83 |
|
|
2022
Q3 | $24.8M | Buy |
85,638
+19,586
| +30% | +$5.64M | 0.49% | 77 |
|
|
2022
Q2 | $18.6M | Buy |
66,052
+13,356
| +25% | +$3.57M | 0.34% | 112 |
|
|
2022
Q1 | $13.8M | Buy |
52,696
+41,677
| +378% | +$9.89M | 0.21% | 141 |
|
|
2021
Q4 | $2.42M | Buy |
11,019
+5,687
| +107% | +$1.11M | 0.03% | 262 |
|
|
2021
Q3 | $968K | Sell |
5,332
-80,314
| -94% | -$15.7M | 0.01% | 516 |
|
|
2021
Q2 | $17.3M | Sell |
85,646
-19,484
| -19% | -$4.08M | 0.2% | 151 |
|
|
2021
Q1 | $22.6M | Buy |
105,130
+37,505
| +55% | +$8.24M | 0.26% | 133 |
|
|
2020
Q4 | $16M | Sell |
67,625
-60,455
| -47% | -$13.9M | 0.18% | 148 |
|
|
2020
Q3 | $34.9M | Buy |
128,080
+42,151
| +49% | +$11.6M | 0.42% | 83 |
|
|
2020
Q2 | $24.9M | Buy |
85,929
+71,259
| +486% | +$19.3M | 0.29% | 116 |
|
|
2020
Q1 | $3.49M | Buy |
14,670
+9,452
| +181% | +$2.17M | 0.05% | 375 |
|
|
2019
Q4 | $1.14M | Sell |
5,218
-5,995
| -53% | -$1.21M | 0.01% | 737 |
|
|
2019
Q3 | $1.9M | Sell |
11,213
-2,600
| -19% | -$460K | 0.02% | 599 |
|
|
2019
Q2 | $2.53M | Hold |
13,813
| – | – | 0.03% | 536 |
|
|
2019
Q1 | $2.54M | Buy |
13,813
+3
| +0% | +$554 | 0.03% | 542 |
|
|
2018
Q4 | $2.29M | Sell |
13,810
-202
| -1% | -$35K | 0.03% | 507 |
|
|
2018
Q3 | $2.7M | Buy |
14,012
+3,100
| +28% | +$552K | 0.03% | 476 |
|
|
2018
Q2 | $1.85M | Sell |
10,912
-2,195
| -17% | -$340K | 0.02% | 571 |
|
|
2018
Q1 | $2.14M | Sell |
13,107
-699
| -5% | -$114K | 0.03% | 514 |
|
|
2017
Q4 | $2.07M | Sell |
13,806
-499
| -3% | -$73.9K | 0.03% | 528 |
|
|
2017
Q3 | $2.17M | Buy |
14,305
+4,500
| +46% | +$677K | 0.03% | 538 |
|
|
2017
Q2 | $1.26M | Buy |
9,805
+299
| +3% | +$36K | 0.02% | 669 |
|
|
2017
Q1 | $1.04M | Buy |
+9,506
| New | +$837K | 0.02% | 713 |
|
Other funds holding VRTX
VCM
VPM
Martingale Asset Management's VRTX Position: Q1 2026 in Review
Martingale Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 3.5% in Q1 2026, buying an estimated $713K and bringing the position to 44,750 shares worth $20M. The position accounts for 0.5% of the portfolio, ranked #67.
Martingale Asset Management first reported a position in VRTX in Q1 2017 and has held it in 37 quarters since. The position peaked at $34.9M in Q3 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Martingale Asset Management held 44,750 shares of Vertex Pharmaceuticals worth $20M as of Q1 2026.
- Martingale Asset Management bought 1,529 Vertex Pharmaceuticals shares in Q1 2026, an estimated $713K.
- Vertex Pharmaceuticals made up 0.5% of Martingale Asset Management's portfolio in Q1 2026, its #67 holding.
- Martingale Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
- Martingale Asset Management's Vertex Pharmaceuticals position peaked at $34.9M in Q3 2020.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.